Taylor Schwartz works collaboratively with clients to develop, design, and execute epidemiological and health economics and outcomes research studies in a variety of therapeutic areas, in addition to healthy policy analyses and medical innovation value assessment studies.

Taylor’s expertise is in epidemiological methods, survey research methods, health policy, and value assessment and frameworks. Prior to joining Avalere, Taylor was a senior research scientist at Precision Health Economics where he conducted health economics research focused on estimating the value of innovative health technologies and examining the impact of policy changes on innovation and population health. He has also worked at Tufts University School of Medicine and the University of California, San Francisco, performing research on chronic and infectious diseases, substance misuse, adolescent risk behaviors, and mental health. He currently holds an adjunct appointment at American University and has held past adjunct appointments at the University of North Carolina, Chapel Hill, Gillings School of Global Public Health; San Francisco State University’s Health Education Department; the University of San Francisco's Politics Department; San Jose State University; and the University of New England, where he taught a variety of courses, including epidemiology, public health, biostatistics, health policy, and research methods.

Taylor received his MPH in epidemiology and biostatistics from Tufts University School of Medicine. He also received his BA in community health and American studies from Tufts University.

Authored Content

Manufacturers of therapeutic alternatives to negotiation-eligible drugs should examine their value and evidence strategy in response to new dynamics.

Current value assessment methods do not effectively and quantitatively include patients’ perspectives in the evaluation of treatment value.